Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Dicpinigaitis (Bronx, United States of America), S. Birring (London, United Kingdom), A. Morice (Cottingham, United Kingdom), J. Smith (Manchester, United Kingdom), I. Pavord (Oxford, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), A. Tzontcheva (Kenilworth, United States of America), Q. Li (Kenilworth, United States of America), A. Martin Nguyen (Kenilworth, United States of America), J. Schelfhout (Kenilworth, United States of America), D. Muccino (Kenilworth, United States of America), C. La Rosa (Kenilworth, United States of America). Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant. 1588

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of reslizumab in adults with severe eosinophilic asthma with =3 exacerbations in the previous year: analyses at weeks 16 and 52 of two placebo-controlled phase 3 trials Source: International Congress 2017 – Asthma epidemiology among children and adults: from biomarkers to ACOS Year: 2017 The Cough Severity Diary in a pooled analysis of two, phase 3 trials of gefapixant in chronic cough Source: Virtual Congress 2021 – Exacerbations of chronic respiratory diseases, including SARS-CoV-2 Year: 2021 Improvements in cough severity and cough-related quality of life in a phase 2 trial (RELIEF) with the P2X3 antagonist BLU-5937 in refractory chronic cough (RCC) Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Effect of 1 month of zopiclone on obstructive sleep apnoea severity and symptoms: a randomised controlled trial Source: Eur Respir J, 52 (1) 1800149; 10.1183/13993003.00149-2018 Year: 2018 Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Patient-reported outcomes (PROs) and reliever use in Japanese and European patients with chronic obstructive pulmonary disease receiving formoterol 4.5 and 9μg twice daily: Results of the OCEAN phase III study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Patient-reported versus objective adherence and exacerbation rates in severe asthma. Source: Virtual Congress 2020 – Clinical parameters in severe asthma Year: 2020 Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016 Prevalence of heart disease in patients hospitalized for an acute exacerbation of COPD: Impact on clinical outcome. A 6 month follow-up study Source: Annual Congress 2011 - COPD management Year: 2011 STEP-UP randomized controlled trial of vapor ablation in patients with severe emphysema: 12 month results Source: International Congress 2016 – Endoscopic lung volume reduction I Year: 2016 Reslizumab for uncontrolled eosinophilic asthma in patients who experienced a single exacerbation in the previous year: sub-analysis of two phase 3 trials Source: International Congress 2017 – Asthma management Year: 2017 A clinical and outcomes assessment of the management of acute episodes of chronic bronchitis (AECB) : the MOSAIC study - baseline characteristics of screened patients Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002 Changes in COPD symptom control questionnaire (CCQ) scores after seven days of treatment with prednisolone of acute exacerbations in hospitalised patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 54s Year: 2003 Minimal important difference of the transition dyspnoea index in a multinational clinical trial Source: Eur Respir J 2003; 21: 267-272 Year: 2003 COPD exacerbations in the phase 3 revefenacin clinical trial program Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Is chronic breathlessness less recognised and treated compared with chronic pain? A case-based randomised controlled trial Source: Eur Respir J, 52 (3) 1800887; 10.1183/13993003.00887-2018 Year: 2018 The Leicester Cough Questionnaire in two phase 3 trials of gefapixant in chronic cough Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021 Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001 Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006